

David N Franz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/497194/publications.pdf>

Version: 2024-02-01

82
papers

10,070
citations

87888

38
h-index

64796

79
g-index

83
all docs

83
docs citations

83
times ranked

6939
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of thoracoabdominal imaging findings in tuberous sclerosis complex. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 124.	2.7	2
2	Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports. <i>Frontiers in Neurology</i> , 2021, 12, 627672.	2.4	7
3	RHOA signaling defects result in impaired axon guidance in iPSC-derived neurons from patients with tuberous sclerosis complex. <i>Nature Communications</i> , 2021, 12, 2589.	12.8	17
4	Lymphangioliomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex. <i>Annals of the American Thoracic Society</i> , 2021, 18, 815-819.	3.2	10
5	Diabetes in Individuals With Tuberous Sclerosis Complex Treated With mTOR Inhibitors. <i>Pediatric Neurology</i> , 2021, 120, 7-10.	2.1	3
6	Prenatal Sirolimus Treatment for Rhabdomyomas in Tuberous Sclerosis. <i>Pediatric Neurology</i> , 2021, 125, 26-31.	2.1	16
7	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. <i>Pediatric Neurology</i> , 2021, 123, 50-66.	2.1	230
8	Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3. <i>Epilepsia</i> , 2021, 62, 3029-3041.	5.1	16
9	Symptom rates and profile clustering in tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). <i>Journal of Neurodevelopmental Disorders</i> , 2021, 13, 60.	3.1	5
10	Congenital Lymphatic Malformation and Aortic Aneurysm in a Patient with TSC2 Mutation. <i>Neuropediatrics</i> , 2020, 51, 057-061.	0.6	12
11	Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex. <i>Pediatric Neurology</i> , 2020, 105, 59-61.	2.1	38
12	mTOR Inhibitor Therapy for Tuberous Sclerosis Complex: Longitudinal Study of Muscle Mass Determined by Abdominal Cross-sectional Imaging with CT and MRI. <i>Radiology Imaging Cancer</i> , 2020, 2, e190091.	1.6	1
13	A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 23.	2.7	69
14	Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA). <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1329-1336.	1.8	20
15	Anticonvulsant Agents: Everolimus. , 2020, , 1-32.		0
16	Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1000-1008.	0.7	31
17	Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 913-925.	2.8	33
18	Everolimus for cognition/autism in children with tuberous sclerosis complex. <i>Neurology</i> , 2019, 93, 51-52.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Clinical Letter: A case report of targeted therapy with sirolimus for NPRL3 epilepsy. Seizure: the Journal of the British Epilepsy Association, 2019, 73, 43-45.	2.0	22
20	Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex. Pediatric Neurology, 2019, 90, 24-30.	2.1	21
21	Renal Lesions in Lymphangiomyomatosis and Tuberous Sclerosis Complex Are Rarely Biologically Aggressive. American Journal of Roentgenology, 2018, 210, W131-W131.	2.2	1
22	Everolimus dosing recommendations for <scp>tuberous sclerosis complexâ€“</scp>associated refractory seizures. Epilepsia, 2018, 59, 1188-1197.	5.1	41
23	The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatric Nephrology, 2018, 33, 101-109.	1.7	37
24	Everolimus for treatment-refractory seizures in TSC. Neurology: Clinical Practice, 2018, 8, 412-420.	1.6	85
25	mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2018, 178, 365-373.	1.6	44
26	Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex â€“ Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy. Frontiers in Pharmacology, 2018, 9, 964.	3.5	22
27	Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. The Lancet Child and Adolescent Health, 2018, 2, 495-504.	5.6	77
28	Calcification in cerebral parenchyma affects pharmaco-resistant epilepsy in tuberous sclerosis. Seizure: the Journal of the British Epilepsy Association, 2018, 60, 86-90.	2.0	20
29	Thoracoabdominal imaging of tuberous sclerosis. Pediatric Radiology, 2018, 48, 1307-1323.	2.0	7
30	Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. European Journal of Paediatric Neurology, 2018, 22, 1066-1073.	1.6	54
31	Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus. Pediatric Neurology, 2017, 72, 81-85.	2.1	17
32	Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor. Journal of Pediatrics, 2017, 187, 318-322.e2.	1.8	22
33	<i>GRIN2B</i> encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. Journal of Medical Genetics, 2017, 54, 460-470.	3.2	190
34	mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. Orphanet Journal of Rare Diseases, 2017, 12, 51.	2.7	38
35	Tuberin Regulates Prostaglandin Receptorâ€“Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells. Molecular Cancer Research, 2017, 15, 1318-1330.	3.4	14
36	Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. PLoS ONE, 2017, 12, e0186235.	2.5	10

#	ARTICLE	IF	CITATIONS
37	Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2165-2172.	2.2	17
38	Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial. <i>Journal of Pediatrics</i> , 2016, 172, 151-155.e1.	1.8	29
39	Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. <i>Lancet</i> , The, 2016, 388, 2153-2163.	13.7	554
40	Long-term treatment of epilepsy with everolimus in tuberous sclerosis. <i>Neurology</i> , 2016, 87, 2408-2415.	1.1	130
41	Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. <i>PLoS ONE</i> , 2016, 11, e0158476.	2.5	146
42	Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. <i>Annals of Neurology</i> , 2015, 78, 929-938.	5.3	130
43	Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. <i>PLoS Genetics</i> , 2015, 11, e1005637.	3.5	209
44	Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. <i>European Journal of Human Genetics</i> , 2015, 23, 1665-1672.	2.8	29
45	Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. <i>Lancet Oncology</i> , The, 2014, 15, 1513-1520.	10.7	152
46	Reply. <i>Annals of Neurology</i> , 2014, 75, 164-165.	5.3	0
47	The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1203-1210.	0.7	79
48	Pharmacologic management of tuberous sclerosis complex-associated subependymal giant cell astrocytomas. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 53-66.	0.8	0
49	Stomatitis incidence and its relationship with efficacy: A meta-analysis of everolimus clinical studies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 151-151.	1.6	1
50	Meta-analysis of stomatitis incidence in everolimus (EVE) clinical studies and its relationship with efficacy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 645-645.	1.6	1
51	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 243-254.	2.1	1,185
52	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 255-265.	2.1	693
53	Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012. <i>Pediatric Neurology</i> , 2013, 49, 439-444.	2.1	157
54	Pharmacotherapeutic Management of Pediatric Gliomas. <i>Paediatric Drugs</i> , 2013, 15, 29-42.	3.1	10

#	ARTICLE	IF	CITATIONS
55	Everolimus in tuberous sclerosis patients with intractable epilepsy: A treatment option?. <i>European Journal of Paediatric Neurology</i> , 2013, 17, 631-638.	1.6	73
56	Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2013, 381, 125-132.	13.7	687
57	Nursing Implications for the Lifelong Management of Tuberous Sclerosis Complex. <i>Journal of Neuroscience Nursing</i> , 2013, 45, 226-242.	1.1	13
58	Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. <i>Neurology</i> , 2013, 80, 574-580.	1.1	180
59	Everolimus for Tumor Recurrence After Surgical Resection for Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex. <i>Journal of Child Neurology</i> , 2013, 28, 602-607.	1.4	22
60	Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. <i>Annals of Neurology</i> , 2013, 74, 679-687.	5.3	332
61	Lymphangioliomyomatosis Screening in Women With Tuberous Sclerosis. <i>Chest</i> , 2013, 144, 578-585.	0.8	129
62	Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. <i>Biologics: Targets and Therapy</i> , 2013, 7, 211.	3.2	55
63	Everolimus alters white matter diffusion in tuberous sclerosis complex. <i>Neurology</i> , 2012, 78, 526-531.	1.1	67
64	Vigabatrin for Childhood Partial-Onset Epilepsies. <i>Pediatric Neurology</i> , 2012, 46, 83-88.	2.1	19
65	Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 294-301.	4.2	48
66	Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10619-10619.	1.6	2
67	Targeting mTOR complex 1 to treat neurological and psychiatric manifestations of tuberous sclerosis complex. <i>Future Neurology</i> , 2011, 6, 261-271.	0.5	3
68	Regression of a Cardiac Rhabdomyoma in a Patient Receiving Everolimus. <i>Pediatrics</i> , 2011, 127, e1335-e1337.	2.1	100
69	Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1181-1192.	2.4	68
70	Research and innovation in the development of everolimus for oncology. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 323-338.	5.0	24
71	Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF-D Levels Decrease. <i>PLoS ONE</i> , 2011, 6, e23379.	2.5	177
72	Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis. <i>New England Journal of Medicine</i> , 2010, 363, 1801-1811.	27.0	906

#	ARTICLE	IF	CITATIONS
73	Utility of [18 F]2-Fluoro-2-Deoxyglucose-PET in Sporadic and Tuberous Sclerosis-Associated Lymphangioliomyomatosis. <i>Chest</i> , 2009, 136, 926-933.	0.8	33
74	Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioliomyomatosis. <i>New England Journal of Medicine</i> , 2008, 358, 140-151.	27.0	1,138
75	Current Management of Tuberous Sclerosis Complex. <i>Paediatric Drugs</i> , 2008, 10, 299-313.	3.1	49
76	Identification of S664 TSC2 Phosphorylation as a Marker for Extracellular Signal-Regulated Kinase-Mediated mTOR Activation in Tuberous Sclerosis and Human Cancer. <i>Cancer Research</i> , 2007, 67, 7106-7112.	0.9	128
77	Levetiracetam as Adjunctive Antiepileptic Therapy for Patients with Tuberous Sclerosis Complex: A Retrospective Open-Label Trial. <i>Journal of Child Neurology</i> , 2006, 21, 53-57.	1.4	37
78	Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. <i>Annals of Neurology</i> , 2006, 59, 490-498.	5.3	572
79	Non-Neurologic Manifestations of Tuberous Sclerosis Complex. <i>Journal of Child Neurology</i> , 2004, 19, 690-698.	1.4	54
80	Lamotrigine Therapy of Epilepsy in Tuberous Sclerosis. <i>Epilepsia</i> , 2001, 42, 935-940.	5.1	41
81	Mutational and Radiographic Analysis of Pulmonary Disease Consistent with Lymphangioliomyomatosis and Micronodular Pneumocyte Hyperplasia in Women with Tuberous Sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 661-668.	5.6	266
82	Autism and the cerebellum: evidence from tuberous sclerosis. <i>Journal of Autism and Developmental Disorders</i> , 2000, 30, 511-517.	2.7	84